" /> SARS-CoV-2 SP modRNA LNP vaccine BNT162a1 - CISMeF





Preferred Label : SARS-CoV-2 SP modRNA LNP vaccine BNT162a1;

NCIt synonyms : BNT162a1 COVID-19 Vaccine; BNT1162a1 SARS-CoV-2 Vaccine;

NCIt related terms : BNT-162A1;

NCIt definition : A formulation consisting of lipid nanoparticle (LNP) encapsulating nucleoside-modified messenger RNA (modRNA) encoding the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) spike glycoprotein (SP), with potential immunizing and anti-COVID-19 activities. Upon injection of SARS-CoV-2 SP modRNA LNP vaccine BNT162a1, the LNPs bind to the plasma membrane of nearby cells and release SARS-CoV-2 SP mRNA into the cell. The mRNA is then translated by the cellular protein translation machinery to produce SARS-CoV-2 SP. This may stimulate the immune system to induce an antibody and T-cell-mediated immune response. This may provide active immunization against SARS-CoV-2 infection. SP, usually found on the surface of SARS-CoV-2, plays an essential role in the infection pathway of the SARS-CoV-2 virus.;

UNII : N38TVC63NU;

CAS number : 2417899-74-0;

Molecule name : BNT 162a1; BNT-162a1;

NCI Metathesaurus CUI : CL1640890;

Details


You can consult :


Nous contacter.
04/05/2025


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.